Strategic partnerships OraSure has recently integrated with Roche to enhance high-throughput molecular testing capabilities, presenting an opportunity to cross-sell combined diagnostic solutions, expand distribution, and engage Roche’s customer base for joint offerings.

Board and leadership Recent board additions and leadership changes, including independent directors, signal evolving governance and strategic focus, offering a chance to position new collaboration and advisory engagements with decision-makers and investment partners.

Diagnostics portfolio With a strong emphasis on rapid tests, sample collection, and stabilization kits (including Colli-Pee Dx with NucleoPrecision technology), target hospitals, clinics, and labs seeking end-to-end testing workflows and pre-analytical solutions.

Global reach Global sales footprint across clinical labs, hospitals, public health and community orgs opens door for expansion into new geographies and government/public health contracts, especially for point-of-need testing and at-home diagnostics.

Financial posture Mid-market revenue scale with substantial funding and notable revenue range, suggesting opportunities for scalable partnerships, co-development, or sponsored pilots with mid-sized health systems and regional distributors.